Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

Published:2022-01-11 Issue:2 Volume:327 Page:138
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Rubino Domenica M.¹,Greenway Frank L.²,Khalid Usman³,O’Neil Patrick M.⁴,Rosenstock Julio⁵,Sørrig Rasmus³,Wadden Thomas A.⁶,Wizert Alicja³,Garvey W. Timothy⁷,Arauz-Pacheco Carlos⁸,Cannon Kevin⁸,Downey H. Jackson⁸,Fitz-Patrick David⁸,Geohas Jeffrey⁸,Gerety Gregg⁸,Gilbert John⁸,Hollander Priscilla⁸,Klein Eric⁸,Laufer Karen⁸,O'Donnell Philip⁸,Rosenblit Paul⁸,Toth Phillip⁸,

Affiliation:

1. Washington Center for Weight Management and Research, Arlington, Virginia

2. Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge

3. Novo Nordisk A/S, Søborg, Denmark

4. Weight Management Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston

5. Dallas Diabetes Research Center at Medical City, Dallas, Texas

6. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia

7. Department of Nutrition Sciences, University of Alabama at Birmingham

8. for the STEP 8 Investigators

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2787907/jama_rubino_2022_oi_210142_1641310203.77797.pdf

Reference36 articles.

1. Once-weekly semaglutide in adults with overweight or obesity.;Wilding;N Engl J Med,2021

2. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.;Davies;Lancet,2021

3. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.;Wadden;JAMA,2021

4. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.;Rubino;JAMA,2021

5. The discovery and development of liraglutide and semaglutide.;Knudsen;Front Endocrinol (Lausanne),2019

Cited by 259 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in peptide-based therapies for obesity and type 2 diabetes;Peptides;2024-03

2. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients;Current Problems in Cardiology;2024-03

3. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial;The Lancet Diabetes & Endocrinology;2024-02

4. Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?;Pharmacological Research;2024-02

5. Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond;Metabolism;2024-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3